SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is actively trending as its community intensely discusses a potential price reversal, with many holding onto hopes for substantial gains following recent market dips. While some vocal participants express frustration and question its long-term viability, others remain confident in its community-driven momentum and look for signs of a breakout, often contrasting its appeal with more infrastructure-focused crypto projects.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending high after securing FDA approval for Yartemlea, marking it as the first and only approved therapy for life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children. The market is buzzing with excitement over this de-risking event, with significant community discussion around a potential short squeeze, a future valuation reset, and speculation about a buyout by Novo Nordisk, given their existing multi-billion dollar partnership.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is a hot topic, facing significant community skepticism with many users labeling it a "scam" or "dead chain" amidst calls to sell. Conversely, proponents point to its research-driven foundation and the recent launch of ecosystem projects like Midnight ($NIGHT) as reasons for a potential rebound. The debate underscores its position as a long-term, community-focused blockchain against a market increasingly demanding high-speed, institutionally compliant solutions.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is experiencing elevated discussion after its major depressive disorder candidate failed a Phase 2 trial, an outcome many investors had anticipated. Community focus has quickly pivoted to the company's epilepsy and obesity programs as the next significant catalysts, alongside positive early data for its cancer drug. This sentiment is reinforced by recent significant insider purchases, signaling strong management confidence in the company's diverse pipeline.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is surging following the announcement of its acquisition by Sanofi, which will integrate its Heplisav-B vaccine and promising shingles candidate into a major pharmaceutical pipeline. While long-term shareholders express mixed feelings about the acquisition price, the community is actively discussing whether the offer fully captures DVAX's value and the implications for its recent licensing agreements in the context of broader biotech M&A.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is trending following the successful closing of an oversubscribed $400 million private placement and major operational milestones, including beginning drilling for its KRONOS microreactor prototype and securing significant R&D incentives. Community discussion highlights the strong institutional backing and positive progress, fueling optimism within the broader nuclear energy sector as demand for advanced microreactors surges, particularly to power AI data centers.

USELESS

USELESS is gaining significant attention following reports of notable insider accumulation and a recent Chainlink CCIP integration enabling cross-chain transfers, signaling increased utility and adoption. The community is extremely bullish, widely discussing the potential for a massive, parabolic run for this meme coin, drawing comparisons to other major crypto success stories.

Aptos is a new, independent high-performance PoS Layer 1 project focused on delivering the safest and most scalable Layer 1 blockchain in the world. The Aptos blockchain leverages the Move programming language and the Move VM for application development, which are created and optimized for blockchain use cases.The team is comprised of the original creators, researchers, designers, and builders of Diem, the blockchain that was first built to serve this purpose. Aptos raised $200m from a16z, Multicoin, Binance and others. Aptos launched Devnet in mid March, incentivized testnet in late May and targets Q3 for mainnet launch.

Aptos

Aptos is a trending topic as discussion intensifies around its role as a high-performance Layer 1, recognized for its robust engineering and dApp capabilities. Simultaneously, significant attention is on Keeta, an emerging Layer 1 praised for its ultra-high transaction speeds, compliance-first design, and crucial fiat integration via a Stripe partnership, positioning it as a complementary, undervalued asset for global financial infrastructure alongside Aptos.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending as the community speculates on the impact of federal cannabis reclassification to Schedule III and the anticipated end of the 280E tax burden. Enthusiasts are rallying around this "Green Revolution" on the Solana ecosystem, envisioning it as a movement against traditional pharmaceutical monopolies. The prevailing sentiment among supporters is captured by the slogan, "Weedcoin - Like Bitcoin but way higher," reflecting strong belief in its potential.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

monday.com is trending amidst a sharp divergence in market sentiment, stemming from a recent earnings report that saw strong operational performance met with concerns over future growth projections. While numerous analysts maintain optimistic ratings and the company announced a significant share repurchase program, community discussion is divided between those who see it as deeply oversold given its healthy balance sheet and enterprise expansion, and those wary of the AI landscape impacting the broader SaaS sector and the actual execution of the buyback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates

IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy

IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for Oct. 24

ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.

New Strong Buy Stocks for Oct. 24: IGC, ASM and More

IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.

IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates

IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates

Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and -7.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

IGC
IGC Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IGC News

IGCIGC Pharma Inc